Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7396 to 7410 of 8218 results

  1. Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

    Discontinued Reference number: GID-TA10783

    Technology appraisal guidance
    Discontinued

  2. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

    Technology appraisal guidance
    Discontinued

  3. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    Discontinued Reference number: GID-HST10033

    Highly specialised technologies guidance
    Discontinued

  4. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

    Technology appraisal guidance
    Discontinued

  5. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    Discontinued Reference number: GID-TA10597

    Technology appraisal guidance
    Discontinued

  6. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development Reference number: GID-TA11228 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development Reference number: GID-TA11277 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    Discontinued Reference number: GID-TA11252

    Technology appraisal guidance
    Discontinued

  9. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Discontinued Reference number: GID-TA11339

    Technology appraisal guidance
    Discontinued

  10. Benralizumab for previously treated severe nasal polyps [ID1659]

    In development Reference number: GID-TA10818 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    Discontinued Reference number: GID-TA11109

    Technology appraisal guidance
    Discontinued

  12. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development Reference number: GID-TA11567 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    Discontinued Reference number: GID-TA10926

    Technology appraisal guidance
    Discontinued

  14. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  15. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued